

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
31 August 2006 (31.08.2006)

PCT

(10) International Publication Number
WO 2006/090915 A1

(51) International Patent Classification:

C07D 213/55 (2006.01) C07D 417/12 (2006.01)
 C07D 213/56 (2006.01) C07D 401/14 (2006.01)
 C07D 401/12 (2006.01) A61P 3/08 (2006.01)
 C07D 413/12 (2006.01) A61K 31/44 (2006.01)
 C07D 405/12 (2006.01) A61K 31/4427 (2006.01)
 C07D 409/12 (2006.01)

COMPANY LIMITED, 10, Wadai, Tsukuba-shi, Ibaraki, 3004293 (JP).

(74) Agent: **TAKASHIMA, Hajime**; Meiji Yasuda Seimei Osaka Midouji Bldg., 1-1, Fushimimachi 4-chome, Chuo-ku, Osaka-shi, Osaka, 5410044 (JP).

(21) International Application Number:

PCT/JP2006/304177

(22) International Filing Date:

24 February 2006 (24.02.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2005-052018 25 February 2005 (25.02.2005) JP

(71) Applicant (for all designated States except US): **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MAEZAKI, Hironobu** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka, 5328686 (JP). **SUZUKI, Nobuhiro** [JP/JP]; c/o TAKEDA PHARMACEUTICAL

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PYRIDYL ACETIC ACID COMPOUNDS

(57) Abstract: The present invention provides a compound represented by the formula (I): wherein R₁ is a C₁-6#191 alkyl group optionally substituted by a C₃-10#191 cycloalkyl group, R₂ is a C₂-6#191 alkyl group, R₃ is a hydrogen atom, a C₁-6#191 alkyl group or a halogen atom, and X is -OR₆ or -NR₄R₅ wherein R₄ and R₆ are each independently a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R₅ is an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an optionally substituted hydroxy group,or R₄ and R₅ optionally form, together with the adjacent nitrogen atom, an optionally substituted nitrogen-containing heterocycle, or a salt thereof. The compound of the present invention has a superior peptidase inhibitory action and is useful as an agent for the prophylaxis or treatment of diabetes and the like.